Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new chief executive officer.
Bremer arrives with more than two decades of pharmaceutical leadership experience, most of it built at the German drug maker Grünenthal, where he rose through a series of senior commercial and strategic roles including Executive Vice President for Early Products and Commercial Opportunities and, later, Interim Chief Commercial Officer reporting directly to the company's chief executive.
Over his career, he has overseen more than US$1 billion in licensing transactions and has led teams of up to 500 people across multiple continents. More recently, he served as Chief Development Officer at Navigo Proteins and was the founding chief executive of the Australian radiopharmaceutical company GAIASO Theranostics. He holds medical and doctoral qualifications along with an MBA from INSEAD, and before entering medicine he competed for Germany as a swimmer at the 1992 Olympics and captained the national team at the 1996 Games.
He takes the helm at a pivotal moment for Neurizon. The company's lead drug candidate, NUZ-001, is being tested in 250 participants as part of Regimen I in the registrational Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in the second quarter of 2027. Enrolment for that arm of the trial is already complete, leaving the company focused on carrying the program through to its conclusion while positioning itself for whatever regulatory, commercial or partnering opportunities may follow.
Interim Executive Chairman Sergio Duchini said Bremer stood out for combining medical and scientific credibility with commercial and business development experience and senior international leadership. He said Bremer understood how to connect clinical development with commercial strategy and long-term value creation, and had built trust across boards, scientific teams, partners and investors throughout his career. Duchini will move from Interim Executive Chair to Non-Executive Chair once Bremer starts, and the two are expected to work closely through the transition.
Bremer will be based in Melbourne and will work with Neurizon's teams in Australia and the United States. He will initially hold the chief executive role without also joining the company's board.
In a statement, Bremer said he was honoured to join Neurizon at such an important point in its development, citing the underlying science behind NUZ-001 and the chance to contribute to a potential new treatment for people living with ALS. He said his priorities would be disciplined execution of the clinical and regulatory program, maintaining strong capital and organisational readiness, and preparing thoughtfully for the strategic pathways that could open up once trial results are known. He added that ALS has a profound impact on patients and their families, and that he looked forward to engaging with the ALS community, shareholders, clinical collaborators, potential partners and the broader Australian biotechnology sector.
